Article

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphoma

2022-04-07

Abstract excerpt

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain novel insights into the basis of clinical response, we performed single-cell transcriptome sequ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 11d098ce-8144-5069-a8d7-97a0812216cf
DOI: 10.1101/2022.04.04.22273422

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaDOI 10.1101/2022.04.04.22273422Read

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read

Functional diversification and dynamics of CAR-T cells in patients with B-ALLSemantic proximity Read

Integrative single-cell multi-omics of CD19-CAR <sup>pos</sup> and CAR <sup>neg</sup> T cells suggest drivers of immunotherapy response in B-cell neoplasiasSemantic proximity Read

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity Read

Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoireSemantic proximity Read

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity Read

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaSemantic proximity Read

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma.Semantic proximity Read

Mapping the evolution of T cell states during response and resistance to adoptive cellular therapySemantic proximity Read

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasiasSemantic proximity Read

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity Read

Two-Stage CD8 <sup>+</sup> CAR T-Cell Differentiation in Patients with Large B-Cell LymphomaSemantic proximity Read